3 completed, 2 recruiting, 2 terminated. 7 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 2, Terminated 2 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow BK Virus Infection: new trials by email Literature Review of BK Virus Infection trials Research Report on BK Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection AIC263029, Placebo - BK Virus Infection, BKV Infection | Phase 2 | Recruiting | AiCuris Anti-infective Cures AG | 24 | 2026-10-05 | 2026-11-10 |
| Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation Brincidofovir - BK Virus Infection, Nephropathy | Phase 2 | Terminated | SymBio Pharmaceuticals | 1 | 2022-10-14 | 2024-12-04 |
| Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105), Placebo - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Terminated | AlloVir | 451 | 2022-03-24 | 2024-05-16 |
| Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel) - BK Virus Nephropathy, BK Virus Infection | Phase 2 | Completed | AlloVir | 61 | 2021-03-22 | 2024-05-16 |
| Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Posoleucel (ALVR105) - Adenovirus Infection, BK Virus Infection | Phase 2 / Phase 3 | Completed | AlloVir | 26 | 2021-01-15 | 2024-05-09 |
| A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients MAU868, Placebo - BK Virus Infection | Phase 2 | Completed | Vera Therapeutics, Inc. | 30 | 2020-08-05 | 2023-06-07 |
| Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis - Acquired Immunodeficiency Syndrome, BK Virus Infection | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2015-07-23 | 2026-09-04 |
Adenoviridae Infections (2) · Cytomegalovirus Infections (2) · Epstein-Barr Virus Infections (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Merkel Cell (1) · Encephalitis, Viral (1) · Kidney Diseases (1) · Neoplasms (1)
DNA Virus Infections (3) · Infections (3) · Tumor Virus Infections (3) · Virus Diseases (3) · Herpesviridae Infections (2) · Urogenital Diseases (2) · Adenocarcinoma (1) · Blood-Borne Infections (1) · Brain Diseases (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Central Nervous System Viral Diseases (1) · Communicable Diseases (1)
Cell Count (1) · brincidofovir (1)
AlloVir (3) · AiCuris Anti-infective Cures AG (1) · M.D. Anderson Cancer Center (1) · SymBio Pharmaceuticals (1) · Vera Therapeutics, Inc. (1)
United States (6) · Canada (2) · Australia (1) · Belgium (1) · France (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
George Chen, MD (1)
PMID 39382091, PMID 38597860, PMID 30304652, PMID 33929874, PMID 38593233, PMID 39352862, PMID 40828617, PMID 42402341